Drug Delivery Strategies for the Treatment of Pancreatic Cancer

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 May 27

PMID 37242560

Authors

Oluwabukunmi Olajubutu

Omotola D Ogundipe

Amusa Adebayo

Simeon K Adesina

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is fast becoming a global menace and it is projected to be the second leading cause of cancer-related death by 2030. Pancreatic adenocarcinomas, which develop in the pancreas' exocrine region, are the predominant type of pancreatic cancer, representing about 95% of total pancreatic tumors. The malignancy progresses asymptomatically, making early diagnosis difficult. It is characterized by excessive production of fibrotic stroma known as desmoplasia, which aids tumor growth and metastatic spread by remodeling the extracellular matrix and releasing tumor growth factors. For decades, immense efforts have been harnessed toward developing more effective drug delivery systems for pancreatic cancer treatment leveraging nanotechnology, immunotherapy, drug conjugates, and combinations of these approaches. However, despite the reported preclinical success of these approaches, no substantial progress has been made clinically and the prognosis for pancreatic cancer is worsening. This review provides insights into challenges associated with the delivery of therapeutics for pancreatic cancer treatment and discusses drug delivery strategies to minimize adverse effects associated with current chemotherapy options and to improve the efficiency of drug treatment.

Citing Articles

Informatics strategies for early detection and risk mitigation in pancreatic cancer patients.

Jin D, Khan N, Gu W, Lei H, Goel A, Chen T Neoplasia. 2025; 60:101129.

PMID: 39842383 PMC: 11763847. DOI: 10.1016/j.neo.2025.101129.

Temoporfin-Conjugated PEGylated Poly(,-dimethylacrylamide)-Coated Upconversion Colloid for NIR-Induced Photodynamic Therapy of Pancreatic Cancer.

Shapoval O, Patsula V, Vetvicka D, Engstova H, Oleksa V, Kabesova M Biomacromolecules. 2024; 25(9):5771-5785.

PMID: 38888278 PMC: 11388470. DOI: 10.1021/acs.biomac.4c00317.

Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer.

Gu X, Minko T Cancers (Basel). 2024; 16(8).

PMID: 38672671 PMC: 11048786. DOI: 10.3390/cancers16081589.

Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma.

Budka J, Debowski D, Mai S, Narajczyk M, Hac S, Rolka K Pharmaceutics. 2024; 16(2).

PMID: 38399336 PMC: 10892429. DOI: 10.3390/pharmaceutics16020283.

References

Xie Q, Jia L, Liu Y, Wei C . Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo. World J Gastroenterol. 2009; 15(6):737-41. PMC: 2653444. DOI: 10.3748/wjg.15.737. View

Cun X, Chen J, Li M, He X, Tang X, Guo R . Tumor-Associated Fibroblast-Targeted Regulation and Deep Tumor Delivery of Chemotherapeutic Drugs with a Multifunctional Size-Switchable Nanoparticle. ACS Appl Mater Interfaces. 2019; 11(43):39545-39559. DOI: 10.1021/acsami.9b13957. View

Carvalho T, Di Molfetta D, Greco M, Koltai T, Alfarouk K, Reshkin S . Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches. Cancers (Basel). 2021; 13(23). PMC: 8657427. DOI: 10.3390/cancers13236135. View

Hafeez U, Parakh S, Gan H, Scott A . Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020; 25(20). PMC: 7587605. DOI: 10.3390/molecules25204764. View

Nishigaki T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hara H . Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. Br J Cancer. 2020; 122(9):1333-1341. PMC: 7189381. DOI: 10.1038/s41416-020-0781-2. View

Arias J . Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem. 2011; 11(1):1-17. DOI: 10.2174/138955711793564024. View

Chen B, Dai W, He B, Zhang H, Wang X, Wang Y . Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics. 2017; 7(3):538-558. PMC: 5327631. DOI: 10.7150/thno.16684. View

Le D, Picozzi V, Ko A, Wainberg Z, Kindler H, Wang-Gillam A . Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019; 25(18):5493-5502. PMC: 7376746. DOI: 10.1158/1078-0432.CCR-18-2992. View

Nagaoka K, Bai X, Ogawa K, Dong X, Zhang S, Zhou Y . Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma. Cancer Lett. 2019; 449:87-98. PMC: 6411448. DOI: 10.1016/j.canlet.2019.02.006. View

10.

Silverman D, Hoover R, Brown L, Swanson G, Schiffman M, Greenberg R . Why do Black Americans have a higher risk of pancreatic cancer than White Americans?. Epidemiology. 2002; 14(1):45-54. DOI: 10.1097/00001648-200301000-00013. View

11.

Li J, Peng L, Chen Q, Ye Z, Zhao T, Hou S . Integrin β1 in Pancreatic Cancer: Expressions, Functions, and Clinical Implications. Cancers (Basel). 2022; 14(14). PMC: 9318555. DOI: 10.3390/cancers14143377. View

12.

Abd-Elgaliel W, Cruz-Monserrate Z, Wang H, Logsdon C, Tung C . Pancreatic cancer-associated Cathepsin E as a drug activator. J Control Release. 2013; 167(3):221-7. PMC: 3638719. DOI: 10.1016/j.jconrel.2013.02.007. View

13.

Di Federico A, Mosca M, Pagani R, Carloni R, Frega G, De Giglio A . Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers (Basel). 2022; 14(10). PMC: 9139656. DOI: 10.3390/cancers14102429. View

14.

Ghaneh P, Kawesha A, Evans J, Neoptolemos J . Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2002; 9(1):1-11. DOI: 10.1007/s005340200000. View

15.

Kamath S, Kalyan A, Kircher S, Nimeiri H, Fought A, Benson 3rd A . Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. Oncologist. 2019; 25(5):e808-e815. PMC: 7216436. DOI: 10.1634/theoncologist.2019-0473. View

16.

Liu R, Li H, Liu L, Yu J, Ren X . Fibroblast activation protein: A potential therapeutic target in cancer. Cancer Biol Ther. 2012; 13(3):123-9. DOI: 10.4161/cbt.13.3.18696. View

17.

Bort G, Lux F, Dufort S, Cremillieux Y, Verry C, Tillement O . EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles. Theranostics. 2020; 10(3):1319-1331. PMC: 6956799. DOI: 10.7150/thno.37543. View

18.

Li H, Du J, Liu J, Du X, Shen S, Zhu Y . Smart Superstructures with Ultrahigh pH-Sensitivity for Targeting Acidic Tumor Microenvironment: Instantaneous Size Switching and Improved Tumor Penetration. ACS Nano. 2016; 10(7):6753-61. DOI: 10.1021/acsnano.6b02326. View

19.

Wang X, Liu Y, Xu W, Jia L, Chi D, Yu J . Irinotecan and berberine co-delivery liposomes showed improved efficacy and reduced intestinal toxicity compared with Onivyde for pancreatic cancer. Drug Deliv Transl Res. 2021; 11(5):2186-2197. DOI: 10.1007/s13346-020-00884-4. View

20.

Fang J, Nakamura H, Maeda H . The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2010; 63(3):136-51. DOI: 10.1016/j.addr.2010.04.009. View